Finding new cancer targets in blood disorders caused by splicing mutations
Official title: Identifying mis-splicing-derived antigens in spliceosomal mutant myelodysplasia and targeting via T-cell receptor therapeutics
Funded at Weill Medical Coll of Cornell Univ · NIH-11015772 · Data updated 2026-11-12
This study is looking at how specific changes in RNA can lead to blood disorders like myelodysplastic syndromes and acute myeloid leukemia, and it aims to find new ways to create treatments that help the immune system target these changes for patients with these conditions.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 22, 2024 |
| Project end | June 21, 2027 |
| Funding year | 2025 |
| Award (this year) | $53,974 |
| NIH project number | 5F30HL172602-02 |
| Project ID | NIH-11015772 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myelodysplastic syndromes or acute myeloid leukemia, particularly those with spliceosomal mutations.
✕Less likely to help
Patients without these specific blood disorders or those not exhibiting spliceosomal mutations may not benefit from this research.
What this research studies
This research investigates how certain mutations in RNA splicing factors contribute to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The team aims to identify tumor antigens generated from mis-spliced mRNAs due to these mutations, which could be targeted by T-cell receptor (TCR) therapeutics. By analyzing patient samples and using advanced techniques like RNA sequencing and immunopeptidomics, the researchers hope to develop new immunization strategies and therapies for patients with these blood disorders.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that specifically target cancer cells in patients with MDS and AML.
How similar studies have gone: Previous research has shown promise in targeting mis-spliced mRNAs for immunotherapy, indicating a potential for success in this novel approach.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Kim, Won Jun — Weill Medical Coll of Cornell Univ
- Study coordinator: Kim, Won Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.